Inhibrx provides INBRX-106 and ozekibart trial updates; Ewing sarcoma FDA meeting planned for H2 2026

Inhibrx Biosciences, Inc.

INBRX-106 HNSCC Phase 2/3: 46 of 60 patients enrolled; completion expected Q1 2026.
NSCLC Phase 1/2 trial completed enrollment of 34 patients in Nov 2025; data immature.
Ozekibart colorectal cancer expansion cohort enrolled 44 patients; PFS data mature Q2 2026.
Ewing sarcoma trial enrollment expected Q2 2026; FDA meeting for accelerated approval planned H2 2026 if trends continue.
No efficacy data released; management cautions datasets lack maturity for conclusions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.